Decreased shedding dipeptidyl peptidase 4 from membrane in Hashimoto's thyroiditis

Xu, Wenjie; Liu, Yongping; Cheng, Xuebing; Huang, Na; Hou, Ningning; Wang, Hongsheng; Han, Fang; Han, Xue; Sun, Xiaodong

doi:10.1016/j.intimp.2020.106315

Cited by 4 publications

(7 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…First, hypothyroidism as a result of HT does not impact on DPP4i efficacy. This is in constant to the prediction that TH induced hypothyroidism reduces DPP4i's efficacy, as patients with HT have reduced shedding of DPP4 from the membrane, as well as decreased DPP4 levels and activity [1]. Our data suggests that plasma glucose control does not rely on DPP4 activity in HT induced hypothyroidism.…”

Section: Discussionsupporting

confidence: 85%

“…However, it is not clear whether in previous studies GLP-1 measurements were only of the active form [2], as assay systems are crucial as it is important to only measure the active form of GLP-1 [5]. On the other hand, proteolytic cleavage of DPP4 at the extracellular region by kallikrein-related peptide 5 (KLK5) has been reported to be an alternative source of serum DPP4 [1]. The serum concentration KLK5 and KLK5 mRNA expression are significantly decreased in patients with HT [1].…”

Section: Discussionmentioning

confidence: 99%

“…On the other hand, proteolytic cleavage of DPP4 at the extracellular region by kallikrein-related peptide 5 (KLK5) has been reported to be an alternative source of serum DPP4 [1]. The serum concentration KLK5 and KLK5 mRNA expression are significantly decreased in patients with HT [1]. It has been reported that patients with T2DM have a higher DPP4 activity and that GLP-1 is degraded compared with patients with normal glucose tolerance [6].…”

Section: Discussionmentioning

confidence: 99%

“…Second, we were not able to compare DPP4 activity and active GLP-1 in patients with T2DM with and without HT. Third, diabetes is correlated significantly with dyslipidemia and atherogenic risk as well as an increase in interferon-γ production [7] and Xu at al reported that interferon-γ increases DPP4 shedding from the membrane [1]. This leads to the possibility that the results may differ in patients at a high risk for atherosclerosis.…”

Section: Discussionmentioning

confidence: 99%

“…IT HAS RECENTLY BEEN REPORTED that in patients with Hashimoto's thyroiditis (HT) have reduced dipeptidyl peptidase-4 (DPP4) shedding from the plasma membrane and decreased serum DPP4 levels and activity [1]. Furthermore, serum glucagon-like peptide (GLP-1) is increased in patients with HT [2], although it is not clear whether this is solely the active form.…”

mentioning

confidence: 99%

See 4 more Smart Citations

In patients with type 2 diabetes the presence of Hashimoto’s thyroiditis reduces the beneficial effect of dipeptidyl peptidase–4 inhibitor on plasma glucose control

et al. 2021

View full text Add to dashboard Cite

In this study, we compared the efficacy of a dipeptidyl peptidase-4 inhibitor (DPP4i) to improve glucose control in patients with type 2 diabetes mellitus (T2DM) with or without Hashimoto's thyroiditis (HT). First, we compared the change in glycated hemoglobin (HbA1c) between the hypothyroid condition (before levothyroxine sodium hydrate [LT4] treatment) and euthyroid condition (after LT4 treatment when patients had achieved euthyroidism for at least six months) in patients with T2DM and HT. Next, we compared the change in HbA1c levels before and six months of DPP4i treatment in patients with T2DM with and without HT. In hypothyroid condition the change in HbA1c after six months of DPP4i treatment was 0.13% ± 0.86%. The change in HbA1c levels from when patients first achieved euthyroidism to after six months in the euthyroid condition was 0.26% ± 0.90%. DPP4i efficacy in patients with T2DM and HT was reduced compared to patients with T2DM but without HT (-0.40 ± 0.90 vs. -0.99 ± 0.5, p = 0.0032). These data suggest that hypothyroidism does not impact on DPP4i efficacy. However, the effect of DPP4i in patients with T2DM and HT was reduced compared to that in T2DM patients without HT. An estimation of thyroid function before prescribing DPP4i may be useful tool for predicting the efficacy of DPP4i, allowing the ruling out complications from HT.

show abstract

Section: Discussionsupporting

confidence: 85%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

See 3 more Smart Citations

In patients with type 2 diabetes the presence of Hashimoto’s thyroiditis reduces the beneficial effect of dipeptidyl peptidase–4 inhibitor on plasma glucose control

et al. 2021

View full text Add to dashboard Cite

show abstract

The serum concentration and activity of DPP4 is positively related with the severity of hyperthyroidism in patients with Graves’ disease

et al. 2023

View full text Add to dashboard Cite

Objective Graves’ disease (GD) is an organ-specific autoimmune disease. The production of anti-thyrotropin receptor antibodies (TRAb) is associated with a loss of immune tolerance. Dipeptidyl peptidase-4 (DPP-4) is expressed on multiple immune cells. This study aimed to investigate the relationship between serum concentration/activity of DPP4 and the severity of hyperthyroidism in GD patients. Methods A total of 82 newly diagnosed drug-naive patients with GD hyperthyroidism, 20 patients with non-autoimmune thyrotoxicosis and 122 age- and sex- matched healthy controls were enrolled. The clinical parameters and serum concentration and activity of DPP4 were measured. Results The GD group had increased serum concentration and activity of DPP4 than the healthy controls and patients with non-autoimmune thyrotoxicosis, while no significant difference was observed in the latter two groups. Multivariate linear regression indicated that the serum concentration/activity of DPP4 were positively associated with FT3, FT4 and TRAb levels in the GD patients. And the positive association between serum concentration/activity of DPP4 and TRAb was remained even after adjustment for confounding factors (all p < 0.05). Conclusions The GD patients had significantly increased serum concentration/activity of DPP4. And the serum concentration/activity of DPP4 was positively associated with the severity of hyperthyroidism in GD patients. Key messages The activity and concentration of DPP4 in patients with Graves’ disease were higher than those in healthy controls. There was a significant positive correlation between serum DPP4 concentration and TRAb levels in patients with Graves’ disease. In patients with Graves ‘disease, serum DPP4 activity was positively correlated with TRAb levels.

show abstract

Assessment of serum dipeptidyl peptidase-IV levels in autoimmune thyroid disease

Zhang

Yang

et al. 2022

J Int Med Res

View full text Add to dashboard Cite

Objective Decreased serum dipeptidyl peptidase-IV (sDPPIV) levels have been reported in patients with autoimmune diseases. However, few studies have analyzed the association between sDPPIV levels and autoimmune thyroid disease (AITD). This study aimed to evaluate the association between sDPPIV levels and three types of AITD: Graves’ disease (GD), Graves’ ophthalmopathy (GO), and Hashimoto’s thyroiditis (HT). Methods Patients newly diagnosed with GD (n = 65), GO (n = 22), and HT (n = 27) and healthy individuals (n = 30) were recruited. Clinical characteristics and thyroid function data were collected. sDPPIV was measured using enzyme-linked immunosorbent assays. Results Compared with controls (786.3 ± 46.95), patients with GD and GO had significantly lower sDPPIV levels (662.2 ± 38.81 and 438.4 ± 31.78). Additionally, sDPPIV levels were negatively associated with antithyroid peroxidase antibody (r = −0.20) and antithyroglobulin antibody (r = −0.19), but there was no significant relationship between thyroid hormone and sDPPIV levels. GO cases were divided by proptosis with and without muscle thickening; sDPPIV levels were lower in the muscle thickening group than those in the without muscle thickening group. Logistic regression analysis showed that sDPPIV was negatively correlated with GO and GD. Conclusions sDPPIV concentrations were abnormal in patients with GD and GO, and reduced sDPPIV expression may be involved in the progression of GO and GD.

show abstract

Decreased shedding dipeptidyl peptidase 4 from membrane in Hashimoto's thyroiditis

Cited by 4 publications

References 23 publications

In patients with type 2 diabetes the presence of Hashimoto’s thyroiditis reduces the beneficial effect of dipeptidyl peptidase–4 inhibitor on plasma glucose control

In patients with type 2 diabetes the presence of Hashimoto’s thyroiditis reduces the beneficial effect of dipeptidyl peptidase–4 inhibitor on plasma glucose control

The serum concentration and activity of DPP4 is positively related with the severity of hyperthyroidism in patients with Graves’ disease

Assessment of serum dipeptidyl peptidase-IV levels in autoimmune thyroid disease

Contact Info

Product

Resources

About